Inozyme Pharma Stock Soars 178.17% on BioMarin Acquisition

On May 16, 2025, Inozyme Pharma's stock surged by 178.17% in pre-market trading, marking a significant milestone for the biopharmaceutical company.

Inozyme Pharma has entered into a merger agreement with BioMarin Pharmaceutical, where BioMarin will acquire Inozyme for $4.00 per share in an all-cash transaction totaling approximately $270 million. This acquisition aims to strengthen BioMarin’s enzyme therapies portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, with potential regulatory approval expected in 2027. The transaction has been approved by both companies’ boards and is anticipated to close in the third quarter of 2025, pending regulatory approval and other conditions.

Inozyme Pharma is a clinical-stage biopharmaceutical company based in Boston, focusing on developing innovative therapeutics targeting the PPi-Adenosine Pathway, crucial for bone health and blood vessel function. Their lead investigational therapy, INZ-701, is an enzyme replacement therapy for ENPP1 Deficiency and is in late-stage clinical development.